close

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It develops DNA-based vaccines and therapeutics for the prevention/treatment of infectious diseases, cardiovascular diseases, and cancer, including Allovectin-7 cancer immunotherapeutic, a Phase III clinical trial product for the treatment of metastatic melanoma; Therapeutic vaccine for cytomegalovirus, a Phase II clinical trial product to prevent viral reactivation and disease after transplant; Prophylactic vaccine for H5N1 pandemic influenza virus, which completed its Phase I clinical trial to protect against infection, disease, and/or viral shedding; Prophylactic vaccine for cytomegalovirus, a preclinical status product, which prevents infection before and during pregnancy to preclude fetal transmission; and Therapeutic vaccine for herpes simplex type 2 virus, a research status product that prevents recurring flare-ups. The company, through corporate collaborations, develops Collategene angiogenic therapy encoding Hepatocyte Growth Factor that induces local growth of blood vessels to restore blood flow to limbs affected by ischemia; Angiogenic therapy encoding Hepatocyte Growth Factor, which completed Phase I clinical trial, induces local growth of blood vessels to restore blood flow to heart affected by ischemia; Apex-IHN prophylactic vaccine that protects farm-raised salmon from infection and disease; and Therapeutic cancer vaccine encoding human tyrosinase, used in adjunct treatment to increase survival time of dogs with oral melanoma. It also has products in Phase I status that treat breast or prostate, colorectal, ovarian, or non-small cell lung cancer; melanoma; or carcinomas of the upper GI tract, colon, kidney, or bladder. Vical Incorporated was founded in 1987 and is based in San Diego, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	3.37
Volume	(mio) 1.09
Volume Avg	(mio) 1.2
52 Week High	5.30
52 Week Low	2.22
PE	N/A
PE (group average)	39
EPS Year	-0.10
EPS change Q/Q	-33.33%
EPS change Q/Q Yr ago	-20%
EPS change Q/Q next Q est	100%
EPS change Y/Y	-18.75%
REV change Q/Q	-79.31%
REV change Q/Q Yr ago	-60%
EPS next Q est	0.00
EPS next Y est	-0.42
Divident Annual	0.00
Dividend Yield	0%